Comparative incidence and outcomes of COVID-19 in kidney or kidney-pancreas transplant recipients versus kidney or kidney-pancreas waitlisted patients: A single-center study.


Journal

Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240

Informations de publication

Date de publication:
08 2021
Historique:
revised: 07 05 2021
received: 01 04 2021
accepted: 10 05 2021
pubmed: 18 5 2021
medline: 5 10 2021
entrez: 17 5 2021
Statut: ppublish

Résumé

COVID-19 epidemiologic studies comparing immunosuppressed and immunocompetent patients may provide insight into the impact of immunosuppressants on outcomes. In this retrospective cohort study, we assembled kidney or kidney-pancreas transplant recipients who underwent transplant from January 1, 2010, to June 30, 2020, and kidney or kidney-pancreas waitlisted patients who were ever on the waitlist from January 1, 2019, to June 30, 2020. We identified laboratory-confirmed COVID-19 until January 31, 2021, and tracked its outcomes by leveraging informatics infrastructure developed for an outcomes research network. COVID-19 was identified in 62 of 887 kidney or kidney-pancreas transplant recipients and 20 of 434 kidney or kidney-pancreas waitlisted patients (7.0% vs. 4.6%, p = .092). Of these patients with COVID-19, hospitalization occurred in 48 of 62 transplant recipients and 8 of 20 waitlisted patients (77% vs. 40%, p = .002); intensive care unit admission occurred in 18 of 62 transplant recipients and 2 of 20 waitlisted patients (29% vs. 10%, p = .085); and 7 transplant recipients were mechanically ventilated and died, whereas no waitlisted patients were mechanically ventilated or died (11% vs. 0%, p = .116). Our study provides single-center data and an informatics approach that can be used to inform the design of multicenter studies.

Sections du résumé

BACKGROUND
COVID-19 epidemiologic studies comparing immunosuppressed and immunocompetent patients may provide insight into the impact of immunosuppressants on outcomes.
METHODS
In this retrospective cohort study, we assembled kidney or kidney-pancreas transplant recipients who underwent transplant from January 1, 2010, to June 30, 2020, and kidney or kidney-pancreas waitlisted patients who were ever on the waitlist from January 1, 2019, to June 30, 2020. We identified laboratory-confirmed COVID-19 until January 31, 2021, and tracked its outcomes by leveraging informatics infrastructure developed for an outcomes research network.
RESULTS
COVID-19 was identified in 62 of 887 kidney or kidney-pancreas transplant recipients and 20 of 434 kidney or kidney-pancreas waitlisted patients (7.0% vs. 4.6%, p = .092). Of these patients with COVID-19, hospitalization occurred in 48 of 62 transplant recipients and 8 of 20 waitlisted patients (77% vs. 40%, p = .002); intensive care unit admission occurred in 18 of 62 transplant recipients and 2 of 20 waitlisted patients (29% vs. 10%, p = .085); and 7 transplant recipients were mechanically ventilated and died, whereas no waitlisted patients were mechanically ventilated or died (11% vs. 0%, p = .116).
CONCLUSIONS
Our study provides single-center data and an informatics approach that can be used to inform the design of multicenter studies.

Identifiants

pubmed: 33998716
doi: 10.1111/ctr.14362
pmc: PMC8209946
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14362

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Kidney Int. 2020 Jun;97(6):1076-1082
pubmed: 32354637
N Engl J Med. 2020 Sep 3;383(10):994
pubmed: 32649078
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
Clin Microbiol Infect. 2014 Sep;20 Suppl 7:102-8
pubmed: 26451405
Am J Transplant. 2020 Jul;20(7):1947-1948
pubmed: 32243698
Am J Transplant. 2020 Jul;20(7):1819-1825
pubmed: 32351040
EGEMS (Wash DC). 2018 Apr 13;6(1):3
pubmed: 29881761
Am J Transplant. 2020 Nov;20(11):2997-3007
pubmed: 32515544
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Am J Nephrol. 2020;51(5):337-342
pubmed: 32222713
J Am Med Inform Assoc. 2014 Jul-Aug;21(4):607-11
pubmed: 24821736
Transplantation. 2014 Jul 27;98(2):187-94
pubmed: 24621539
Transplantation. 2018 Jun;102(6):898-899
pubmed: 29677079
N Engl J Med. 2020 Jun 18;382(25):2475-2477
pubmed: 32329975
J Am Soc Nephrol. 2017 Apr;28(4):1314-1325
pubmed: 27821629
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
J Am Soc Nephrol. 2020 Jun;31(6):1150-1156
pubmed: 32317402
Am J Transplant. 2021 Apr;21(4):1576-1585
pubmed: 33043597
Am J Transplant. 2020 Nov;20(11):3008-3018
pubmed: 32780493
Am J Transplant. 2007 May;7(5):1209-14
pubmed: 17286615
Am J Kidney Dis. 2020 Jul;76(1):141-143
pubmed: 32240718
Kidney Int. 2020 Jun;97(6):1083-1088
pubmed: 32354634
Clin Transplant. 2021 Aug;35(8):e14362
pubmed: 33998716
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
Clin Infect Dis. 2018 Feb 1;66(4):608-611
pubmed: 29028978

Auteurs

Carlos A Q Santos (CAQ)

Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.

Yoona Rhee (Y)

Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.

Edward F Hollinger (EF)

Division of Abdominal Transplantation, Department of Surgery, Rush University Medical Center, Chicago, IL, USA.

Oyedolamu K Olaitan (OK)

Division of Abdominal Transplantation, Department of Surgery, Rush University Medical Center, Chicago, IL, USA.

Erik Schadde (E)

Division of Abdominal Transplantation, Department of Surgery, Rush University Medical Center, Chicago, IL, USA.

Vasil Peev (V)

Division of Nephrology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.

Samuel N Saltzberg (SN)

Division of Nephrology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.

Martin Hertl (M)

Division of Abdominal Transplantation, Department of Surgery, Rush University Medical Center, Chicago, IL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH